Description
Novelix Pharmaceuticals Limited lists 15,45,000 equity shares issued at Rs. 20/- on preferential basis pursuant to conversion of warrants, with lock-in periods until June 2026 and 2027.
Summary
BSE has approved the listing of 15,45,000 new equity shares of Novelix Pharmaceuticals Limited (Scrip Code: 536565) issued on preferential basis to Promoter and Non-Promoter following conversion of warrants. The shares will commence trading from November 27, 2025, and rank pari-passu with existing equity shares.
Key Points
- Total New Shares Listed: 15,45,000 equity shares of Rs. 10/- each
- Issue Price: Rs. 20/- per share (including premium of Rs. 10/-)
- Allotment Mode: Preferential basis pursuant to warrant conversion
- Allottees: Promoter and Non-Promoter categories
- Date of Allotment: August 14, 2025
- Distinctive Numbers: 12935001 to 14480000
- ISIN: INE314I01036
- Trading Commencement: November 27, 2025 (Thursday)
Regulatory Changes
No regulatory changes introduced. This is a standard listing notification following preferential allotment procedures.
Compliance Requirements
Lock-in Period Compliance:
- Trading members must ensure compliance with lock-in restrictions for the newly listed shares
- Shares must not be traded before their respective lock-in expiry dates
Important Dates
| Event | Date |
|---|---|
| Allotment Date | August 14, 2025 |
| Trading Commencement | November 27, 2025 |
| Lock-in Expiry (6,45,000 shares - Dist. Nos. 13835001 to 14480000) | June 30, 2026 |
| Lock-in Expiry (9,00,000 shares - Dist. Nos. 12935001 to 13835000) | June 30, 2027 |
Impact Assessment
Market Impact: Low - The preferential allotment represents a modest capital raise through warrant conversion. The staggered lock-in periods (58.25% locked until June 2027 and 41.75% until June 2026) will limit immediate selling pressure.
Shareholder Impact: The shares rank pari-passu with existing equity, providing equal voting and dividend rights. Existing shareholders will experience dilution from the 15.45 lakh new shares.
Liquidity Impact: Minimal immediate impact on free float as all shares are subject to lock-in restrictions for at least 7-19 months from the trading commencement date.
Impact Justification
Routine listing of preferential allotment shares from warrant conversion for a single company with modest share count and lock-in restrictions.